Conference Call Scheduled for Wednesday, April 24 at 4:30 p.m. Eastern Time
SAN
DIEGO, April 17, 2024 /PRNewswire/ -- Viking
Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage
biopharmaceutical company focused on the development of novel
therapies for metabolic and endocrine disorders, today announced
that the company will release financial results for the first
quarter 2024 after the market close on Wednesday, April 24, 2024.
The company will host a conference call to discuss financial
results and general corporate updates beginning at 4:30 p.m. Eastern Time on Wednesday, April 24,
2024. To participate on the conference call, please dial (844)
850-0543 from the U.S. or (412) 317-5199 from outside the U.S. In
addition, following the completion of the call, a telephone replay
will be accessible until May 1, 2024
by dialing (877) 344-7529 from the U.S. or (412) 317-0088 from
outside the U.S. and entering replay access code
#8359459. Those interested in listening to the conference call
live via the internet may do so by visiting the Webcasts page of
Viking's website at http://ir.vikingtherapeutics.com/webcasts. An
archive of the webcast will also be available on the Webcasts page
of the company's website for 30 days.
About Viking Therapeutics, Inc.
Viking Therapeutics is a clinical-stage biopharmaceutical
company focused on the development of novel first-in-class or
best-in-class therapies for the treatment of metabolic and
endocrine disorders, with three compounds currently in clinical
trials. Viking's research and development activities leverage
its expertise in metabolism to develop innovative therapeutics
designed to improve patients' lives. The company's clinical
programs include VK2809, a novel, orally available, small molecule
selective thyroid hormone receptor beta agonist for the treatment
of lipid and metabolic disorders, which is currently being
evaluated in a Phase 2b study for the treatment of
biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis.
In a Phase 2a trial for the treatment of non-alcoholic fatty liver
disease (NAFLD) and elevated LDL-C, patients who received VK2809
demonstrated statistically significant reductions in LDL-C and
liver fat content compared with patients who received placebo. The
company is also developing VK2735, a novel dual agonist of the
glucagon-like peptide 1 (GLP-1) and glucose-dependent
insulinotropic polypeptide (GIP) receptors for the potential
treatment of various metabolic disorders. Data from a Phase 1 and a
Phase 2 trial evaluating VK2735 (dosed subcutaneously) for obesity
demonstrated an encouraging safety and tolerability profile as well
as positive signs of clinical benefit. The company is also
evaluating an oral formulation of VK2735 in a Phase 1 trial. In the
rare disease space, the company is developing VK0214, a novel,
orally available, small molecule selective thyroid hormone receptor
beta agonist for the potential treatment of X-linked
adrenoleukodystrophy (X-ALD). VK0214 is currently being
evaluated in a Phase 1b clinical trial in patients with
the adrenomyeloneuropathy (AMN) form of X-ALD. The company holds
exclusive worldwide rights to a portfolio of five therapeutic
programs, including VK2809 and VK0214, which are based on small
molecules licensed from Ligand Pharmaceuticals Incorporated.
For more information about Viking Therapeutics, please
visit www.vikingtherapeutics.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-report-financial-results-for-first-quarter-2024-on-april-24-2024-302119720.html
SOURCE Viking Therapeutics, Inc.